ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Advisors tell NCI to rethink contracts for clinical trials cooperative group tissue banks

November 21, 2003

Solomon Gard’s Questions/Answers

January 2, 1981

ACS Professors; Connie Mack Is Chairman Of Moffitt Board.

February 9, 2001

Obituaries: Fritz Bach, 77, and William Wolff, 94

September 9, 2011

Newest NIH Institute, NIBIB, Gets An Acting Director.

May 11, 2001

In Brief: Hammond Honored By ACS; SEER Celebrates 20th Anniversary With Symposium Dec. 8

December 3, 1993